Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Viridian Therapeutics Inc (VRDN)

221 + Investors. Track Smart Money conviction in VRDN. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -3
Streak
1Q ▼
Buyers last Q
52%

Smart Money Signals — VRDN

Based on 222 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their VRDN positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
🏔️

At the ownership peak (99% of max)

99% of all-time peak
222 hedge funds hold VRDN right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +28% more funds vs a year ago

fund count last 6Q
+48 new funds entered over the past year (+28% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 52% buying

128 buying118 selling
Last quarter: 128 funds bought or added vs 118 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
⚠️

Fewer new buyers each quarter (-29 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 22 → 15 → 76 → 47. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

42% of holders stayed for 2+ years

■ 42% conviction (2yr+) ■ 25% medium ■ 33% new
93 out of 222 hedge funds have held VRDN for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💎

Buying through price weakness — shares +4%, value -34%

Value
-34%
Shares
+3%
Last quarter: funds added +4% more shares while total portfolio value only changed -34%. Institutions were buying while the price was falling — a high-conviction accumulation signal. They're deliberately loading up on the dip.
🚀

Acceleration phase — new buyers rushing in

26 → 22 → 15 → 76 → 47 new funds/Q
New funds entering each quarter: 22 → 15 → 76 → 47. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Veteran-anchored — 49% veterans vs 34% newcomers

■ 49% veterans ■ 17% 1-2yr ■ 34% new
Entry-cohort mix of 228 holders: 112 (49%) are 2+ year veterans, 39 entered 1–2 years ago, and 77 (34%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 47% AUM from top-100 funds

47% from top-100 AUM funds
46 of 222 holders are among the 100 largest funds by AUM, controlling 47% of total institutional value in VRDN. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
4.4
out of 10
Moderate Exit Risk
Exit risk score 4.4/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — VRDN

In 2026 Q1, 128 hedge funds were net buyers of VRDN (47 opened a new position, 81 added to an existing one), while 118 reduced or exited (68 trimmed, 50 sold completely) — a 52% buyer ratio, indicating a slight buying edge. 47% of total institutional value in VRDN is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: -3 funds (more exits than new entries). Total institutional holders: 222.

Hedge Fund Ownership: VRDN

How many hedge funds hold VRDN — quarterly history vs. share price
Quarterly hedge fund ownership of VRDN vs. share price

Market Analysis: VRDN

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: VRDN

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Viridian Therapeutics Inc (VRDN) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much VRDN has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 46d ago
VRDN
+20.2%
XLV
+5.5%

VRDN outperformed XLV by +14.7% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 1d ago
VRDN
+0.0%
XLV
+0.0%

Since the filing became public, VRDN outperformed XLV by +0.0% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

27 top-rated funds 5 high-conviction
Consensus
6.3
/ 10
breadth
×
Elite
3.8
/ 10
conviction
Hedge Fund Positioning: VRDN
2026 Q2 Stats Unlock in 4 days 221 + Investors

Track Smart Money conviction in VRDN. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 221 224 -1.34%
13F Shares 112M 108M 3.84%
Total Value $2.13B $3.25B -34.43%
New Positions 47 76 -29
Increased Positions 80 83 -3
Closed Positions 50 16 +34
Reduced Positions 65 45 +20
Total Calls 3 2 50.0%
Total Puts 3 3 -
PUT/CALL Ratio 1.0 1.5 Neutral

Statistics: VRDN

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

221 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in VRDN. Verified SEC 13F-HR filings.

QUARTER:
2026 Q2 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 VRDN holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Kynam Capital Management, LP 6.55% 6,453,877 $118.6M
2 Fairmount Funds Management LLC 6.18% 5,090,928 $93.5M
3 Elmind Capital, LP 4.55% 984,931 $18.1M
4 First Turn Management, LLC 3.28% 1,670,000 $30.7M
5 Bellevue Group AG 2.60% 6,731,909 $123.7M
6 Parkman Healthcare Partners LLC 2.59% 1,377,576 $25.3M
7 Yiheng Capital Management, L.P. 2.53% 400,464 $7.4M
8 Paradigm Biocapital Advisors LP 2.31% 6,723,788 $123.5M
9 Novo Holdings A/S 2.28% 2,135,000 $39.2M
10 Caligan Partners LP 1.90% 2,193,981 $40.3M
11 Venrock Adviser, LLC 1.81% 3,257,917 $59.8M
12 Knott David M Jr 1.76% 181,000 $3.3M
13 KVP Capital Advisors, LP 1.69% 125,000 $2.3M
14 Tang Capital Management LLC 1.50% 1,792,626 $32.9M
15 Rice Hall James & Associates, LLC 1.05% 1,175,906 $21.6M
16 Deep Track Capital, LP 0.96% 3,592,740 $66.0M
17 Ikarian Capital, LLC 0.84% 425,000 $7.8M
18 Eversept Partners, LP 0.79% 831,142 $15.3M
19 Blue Owl Capital Holdings LP 0.72% 260,000 $4.8M
20 Verdad Advisers, LP 0.68% 38,722 $711K
21 HighVista Strategies LLC 0.67% 159,885 $2.9M
22 Privium Fund Management B.V. 0.59% 173,516 $3.2M
23 Avoro Capital Advisors LLC 0.41% 2,500,000 $45.9M
24 Bayforest Capital Ltd 0.34% 19,775 $363K
25 Merck & Co., Inc. 0.33% 93,414 $1.7M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Viridian Therapeutics Inc (VRDN)

What does the Smart Money Trend signal show for VRDN?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their VRDN positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for VRDN?

Slight buying edge — 52% buying: Last quarter: 128 funds bought or added vs 118 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for VRDN holders?

Elite ownership — 47% AUM from top-100 funds: 46 of 222 holders are among the 100 largest funds by AUM, controlling 47% of total institutional value in VRDN. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held VRDN?

42% of holders stayed for 2+ years: 93 out of 222 hedge funds have held VRDN for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Viridian Therapeutics Inc (VRDN) following the 2026 Q2 hedge fund 13F filings?

As of today, VRDN has moved +0.0% since the 2026 Q2 13F filing date (August 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (June 30, 2026), VRDN has gained +20.2% vs +5.5% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →